

John M Ringman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/205001/publications.pdf>

Version: 2024-02-01

82
papers

8,865
citations

147801

31
h-index

91884

69
g-index

88
all docs

88
docs citations

88
times ranked

12220
citing authors

#	ARTICLE	IF	CITATIONS
1	Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1754-1764.	0.8	4
2	Locus coeruleus integrity is related to tau burden and memory loss in autosomal-dominant Alzheimer's disease. <i>Neurobiology of Aging</i> , 2022, 112, 39-54.	3.1	49
3	Enhanced Association of Tau Pathology and Cognitive Impairment in Mild Cognitive Impairment Subjects with Behavior Symptoms. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 557-568.	2.6	3
4	Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology. <i>Brain</i> , 2022, 145, 3594-3607.	7.6	20
5	Cerebroarterial pulsatility and resistivity indices are associated with cognitive impairment and white matter hyperintensity in elderly subjects: A phase-contrast MRI study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 670-683.	4.3	14
6	Reaction time and response inhibition in autosomal dominant Alzheimer's disease. <i>Brain and Cognition</i> , 2021, 147, 105656.	1.8	7
7	Cerebral Amyloid Angiopathy-related Inflammation Presenting With a Cystic Lesion in Young-onset Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2021, 35, 265-268.	1.3	5
8	Mark VCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols. <i>Alzheimer's and Dementia</i> , 2021, 17, 704-715.	0.8	42
9	My backpack is so heavy: Experiences of Latino caregivers of family with early-onset Alzheimer's. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1539-1547.	2.6	5
10	Volumetric distribution of perivascular space in relation to mild cognitive impairment. <i>Neurobiology of Aging</i> , 2021, 99, 28-43.	3.1	45
11	Comparing amyloid- β^2 plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. <i>Acta Neuropathologica</i> , 2021, 142, 689-706.	7.7	15
12	Past, present and future role of retinal imaging in neurodegenerative disease. <i>Progress in Retinal and Eye Research</i> , 2021, 83, 100938.	15.5	60
13	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. <i>Lancet Neurology</i> , The, 2021, 20, 615-626.	10.2	26
14	Evaluation of Cerebral Blood Flow Measured by 3D PCASL as Biomarker of Vascular Cognitive Impairment and Dementia (VCID) in a Cohort of Elderly Latinx Subjects at Risk of Small Vessel Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 627627.	2.8	25
15	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1632-e1645.	1.1	16
16	Differential correlation of white matter hyperintensity with Alzheimer's pathology within A/T groups. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
17	The relationship between blood-brain barrier permeability and cerebral blood flow in cognitive impairment. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
18	Emotional detachment, gait ataxia, and cerebellar dysconnectivity associated with compound heterozygous mutations in the SPG7 gene. <i>Neurocase</i> , 2020, 26, 299-304.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Lower retinal capillary density in minimal cognitive impairment among older Latinx adults. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12071.	2.4	10
20	Comparison Between Blood-Brain Barrier Water Exchange Rate and Permeability to Gadolinium-Based Contrast Agent in an Elderly Cohort. <i>Frontiers in Neuroscience</i> , 2020, 14, 571480.	2.8	30
21	Neuropsychiatric symptoms in early stage autosomal dominant and sporadic Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044427.	0.8	0
22	Neurodegenerative substrate of behavioral changes in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045033.	0.8	0
23	Alteration of perivascular spaces in early cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e045605.	0.8	2
24	The Spanish and english NIH Toolbox in autosomal dominant Alzheimer's disease: A preliminary report. <i>Alzheimer's and Dementia</i> , 2020, 16, e046752.	0.8	0
25	Lower MRI-indexed locus coeruleus integrity in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e047676.	0.8	3
26	Probing Estrogen Sulfotransferase-Mediated Inflammation with [11C]-PiB in the Living Human Brain. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1023-1033.	2.6	10
27	APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. <i>Nature</i> , 2020, 581, 71-76.	27.8	705
28	A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2020, 16, 821-830.	0.8	43
29	A probabilistic atlas of locus coeruleus pathways to transentorhinal cortex for connectome imaging in Alzheimer's disease. <i>NeuroImage</i> , 2020, 223, 117301.	4.2	24
30	1H MRS spectroscopy in preclinical autosomal dominant Alzheimer disease. <i>Brain Imaging and Behavior</i> , 2019, 13, 925-932.	2.1	17
31	A mixed-methods study of cultural beliefs about dementia and genetic testing among Mexicans and Mexican-Americans at risk for autosomal dominant Alzheimer's disease. <i>Journal of Genetic Counseling</i> , 2019, 28, 921-932.	1.6	12
32	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2019, 142, 1429-1440.	7.6	36
33	Homozygosity for the A431E mutation in PSEN1 presenting with a relatively aggressive phenotype. <i>Neuroscience Letters</i> , 2019, 699, 195-198.	2.1	8
34	Mapping water exchange across the blood-brain barrier using 3D diffusion-prepared arterial spin labeled perfusion MRI. <i>Magnetic Resonance in Medicine</i> , 2019, 81, 3065-3079.	3.0	80
35	Seizures as an early symptom of autosomal dominant Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 76, 18-23.	3.1	27
36	Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. <i>Nature Medicine</i> , 2019, 25, 270-276.	30.7	987

#	ARTICLE	IF	CITATIONS
37	Historical Migration revealed through a Case of Autosomal Dominant Alzheimer's Disease. Puerto Rico Health Sciences Journal, 2019, 38, 144-147.	0.2	0
38	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. Brain, 2018, 141, 1486-1500.	7.6	79
39	Regional association of pCASL-MRI with FDG-PET and PiB-PET in people at risk for autosomal dominant Alzheimer's disease. NeuroImage: Clinical, 2018, 17, 751-760.	2.7	27
40	A probabilistic atlas of human brainstem pathways based on connectome imaging data. NeuroImage, 2018, 169, 227-239.	4.2	71
41	P4131: ATTITUDES TOWARD GENETIC TESTING AND CLINICAL TRIALS IN MEXICAN FAMILIES AT RISK OF AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1489.	0.8	0
42	P3276: PYRAMIDAL SIGNS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1183.	0.8	0
43	P2100: IMPACT OF HYPERTENSION ON INTRACRANIAL ARTERIAL COMPLIANCE IN A LATINO COHORT. Alzheimer's and Dementia, 2018, 14, P706.	0.8	0
44	P2278: TRANSCALLOSAL CONDUCTION AND CENTRAL MOTOR CONDUCTION IN PEOPLE WITH A FAMILY HISTORY OF AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P785.	0.8	0
45	<sc>CSF</sc> progranulin increases in the course of Alzheimer's disease and is associated with <sc>TREM</sc> 2, neurodegeneration and cognitive decline. EMBO Molecular Medicine, 2018, 10, .	6.9	64
46	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1427-1437.	0.8	51
47	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology, 2018, 91, e1295-e1306.	1.1	193
48	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. PLoS ONE, 2018, 13, e0195838.	2.5	51
49	A comparison of theoretical and statistically derived indices for predicting cognitive decline. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 171-181.	2.4	10
50	Update on Alzheimer's and the Dementias. Neurologic Clinics, 2017, 35, 171-174.	1.8	10
51	Alzheimer and the Dementias. Neurologic Clinics, 2017, 35, ix-x.	1.8	2
52	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. Scientific Reports, 2017, 7, 1225.	3.3	42
53	Patient and caregiver reactions to clinical amyloid imaging. Alzheimer's and Dementia, 2017, 13, 924-932.	0.8	30
54	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783

#	ARTICLE	IF	CITATIONS
55	[P2â€“489]: TOWARD AUGMENTING THE UNDERSTANDING OF GENETICS IN MEXICANS AT RISK OF AUTOSOMAL DOMINANT ALZHEIMER DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P827.	0.8	0
56	[P1â€“542]: CULTURAL BELIEFS ABOUT ALZHEIMER'S DISEASE IN MEXICAN AND MEXICAN-AMERICAN FAMILIES WITH AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P500.	0.8	0
57	[O1â€“02â€“04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P186.	0.8	0
58	Attitudes toward clinical trials across the Alzheimer's disease spectrum. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 81.	6.2	33
59	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. <i>PLoS ONE</i> , 2016, 11, e0152082.	2.5	45
60	Are Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease â€œSeparate but Equalâ€?. <i>JAMA Neurology</i> , 2016, 73, 1060.	9.0	2
61	Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). <i>Lancet Neurology</i> , The, 2016, 15, 1317-1325.	10.2	87
62	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. <i>Annals of Neurology</i> , 2016, 79, 929-939.	5.3	381
63	Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 284-290.	1.7	71
64	Assessing intracranial vascular compliance using dynamic arterial spin labeling. <i>NeuroImage</i> , 2016, 124, 433-441.	4.2	35
65	A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 50.	6.2	10
66	Use of the MoCA in Detecting Early Alzheimer's Disease in a Spanish-Speaking Population with Varied Levels of Education. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015, 5, 85-95.	1.3	31
67	A Multiancestral Genome-Wide Exome Array Study of Alzheimer Disease, Frontotemporal Dementia, and Progressive Supranuclear Palsy. <i>JAMA Neurology</i> , 2015, 72, 414.	9.0	37
68	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2015, 85, 790-798.	1.1	27
69	Daily Activity Abilities in MCI, Alzheimer's Disease, and Healthy Controls. <i>GeroPsych: the Journal of Gerontopsychology and Geriatric Psychiatry</i> , 2015, 28, 191-200.	0.5	12
70	Effect of Potent Î³-Secretase Modulator in Human Neurons Derived From Multiple Presenilin 1-Induced Pluripotent Stem Cell Mutant Carriers. <i>JAMA Neurology</i> , 2014, 71, 1481.	9.0	84
71	The â€œAlzheimer's Typeâ€-Profile of Semantic Clustering in Amnesic Mild Cognitive Impairment. <i>Journal of the International Neuropsychological Society</i> , 2014, 20, 402-412.	1.8	16
72	Clinical Predictors of Severe Cerebral Amyloid Angiopathy and Influence of <i>APOE</i> Genotype in Persons With Pathologically Verified Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 878.	9.0	50

#	ARTICLE	IF	CITATIONS
73	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1111.	9.0	112
74	Symptom onset in autosomal dominant Alzheimer disease. Neurology, 2014, 83, 253-260.	1.1	391
75	Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment Strategies. Current Neurology and Neuroscience Reports, 2014, 14, 499.	4.2	70
76	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. New England Journal of Medicine, 2012, 367, 795-804.	27.0	3,005
77	Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimer's Research and Therapy, 2010, 3, 1.	6.2	424
78	Mosaicism for Trisomy 21 in a Patient With Young-Onset Dementia. Archives of Neurology, 2008, 65, 412-5.	4.5	35
79	Current and Emerging Pharmacological Treatment Options for Dementia. Behavioural Neurology, 2006, 17, 5-16.	2.1	60
80	The A431E mutation in PSEN1 causing Familial Alzheimer's Disease originating in Jalisco State, Mexico: an additional fifteen families. Neurogenetics, 2006, 7, 277-279.	1.4	62
81	What the Study of Persons At Risk for Familial Alzheimer's Disease Can Tell Us About the Earliest Stages of the Disorder: A Review. Journal of Geriatric Psychiatry and Neurology, 2005, 18, 228-233.	2.3	37
82	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 0, , .	0.8	2